No study has examined the KLOW combination
There is no in vitro, animal or human study of KPV + GHK-Cu + BPC-157 + TB-500 administered together. Every study-tier claim below belongs to a single component in isolation.
PrecisePep/Blends & Stacks/KLOW
Regenerative Blend
KLOW
KPV + GHK-Cu + BPC-157 + TB-500 · GLOW + KPV
A four-component regenerative blend: suppress the inflammation, mobilise the repair cells, build the blood supply, remodel the matrix. Four separate evidence bases stitched into one narrative and one vial.
00 Overview
KLOW is GLOW with KPV added. GLOW — GHK-Cu, BPC-157, TB-500 — was the original three-part regenerative blend, targeting structural repair and aesthetics. It had no immune-modulating component, and the argument for KLOW is that chronic inflammatory signalling actively obstructs resolution: without suppressing it, the other three peptides are working against a headwind.
The narrative is genuinely elegant. KPV puts out the fire. TB-500 mobilises repair cells and clears the way. BPC-157 builds the vascular supply to feed the tissue. GHK-Cu lays down and remodels the structural matrix. Four mechanisms, four stages of wound healing, one injection.
It is also a narrative rather than a finding. No study has examined this combination. Every claim about KLOW is assembled from four separate literatures — three of which are predominantly rodent, and one of which (GHK-Cu) has good human evidence for a completely different route of administration. The sequencing story is post-hoc reasoning applied to a product, not the reason the product exists.
What a blend costs you
A blend removes the ability to titrate components independently, to identify which component is producing an effect or an adverse effect, and to stop one without stopping all four. It also means the copper load is fixed by someone else's ratio decision. The convenience is real; so is the loss of control.
// Mechanism of action
The proposed mechanism of KLOW is the sequential mechanism of wound healing, with one component assigned to each phase.
Phase 1 — inflammation control (KPV). NF-κB is the master transcriptional switch for inflammatory cytokine production. KPV is taken up intracellularly and suppresses its activation, reducing TNF-α, IL-1β and IL-6 output at source. In chronic injury, persistent low-grade inflammation is what prevents progression to the proliferative phase.
Phase 2 — cell mobilisation (TB-500). Actin regulation permits cytoskeletal remodelling and therefore cell migration. Endothelial cells, keratinocytes and progenitor populations move toward the injury.
Phase 3 — vascular supply (BPC-157). VEGFR2 upregulation and nitric oxide signalling drive angiogenesis, delivering oxygen and substrate to tissue that is about to be rebuilt.
Phase 4 — matrix remodelling (GHK-Cu). Collagen and elastin synthesis paired with matrix metalloproteinase activity: remove damaged matrix, replace it with new. Copper-dependent lysyl oxidase cross-links the result.
The claimed practical bonus. BPC-157 is reported in community use to blunt the notorious injection-site sting of GHK-Cu. This is an observation, not a characterised pharmacological interaction, but it is consistently reported and is one reason the blend is tolerated better than standalone copper peptide.
// What is in it
A blend is not a compound. It is several compounds sharing a vial, and each one carries its own evidence base, dose-response curve and risk profile. Study them individually before studying them together.
| Component | Share of blend | Role in the blend | Monograph link |
|---|---|---|---|
| KPV Lys-Pro-Val |
10 mg of 80 (12.5%) | Halts the inflammatory loop — intracellular NF-κB suppression, cytokine reduction, mast-cell stabilisation. The addition that turns GLOW into KLOW. | Monograph |
| GHK-Cu Copper tripeptide |
50 mg of 80 (62.5%) | Extracellular matrix remodelling — collagen, elastin, decorin and glycosaminoglycan synthesis, coupled with MMP-driven removal of damaged matrix. Carries the copper. | Monograph |
| BPC-157 Pentadecapeptide |
10 mg of 80 (12.5%) | Angiogenesis and local repair signalling — VEGFR2 upregulation, nitric oxide, fibroblast recruitment, gut-barrier restoration. | Monograph |
| TB-500 Thymosin β4 fragment |
10 mg of 80 (12.5%) | Systemic cell mobilisation — actin regulation driving migration of repair cells to injury, plus anti-fibrotic signalling. | Monograph |
Blend arithmetic
The common presentation is an 80 mg vial split 50 mg GHK-Cu plus 10 mg each of BPC-157, TB-500 and KPV. Note what that means: the blend is 62.5% copper peptide by mass. It is a GHK-Cu product with three repair peptides in it, not four components in balance.
At the widely circulated 3.25 mg daily dose that works out to roughly 2.03 mg GHK-Cu and 406 mcg each of BPC-157, TB-500 and KPV per day, with a full 80 mg vial lasting about 25 days. The GHK-Cu fraction alone lands inside the standalone community range for copper peptide, which is why the copper-load and zinc-balance questions on this page are not theoretical.
Ratios still vary between suppliers and very few certificates of analysis state the split. Use the blend mode of the calculator to rescale to whatever vial and ratio you actually have.
01 Reported benefits
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Component evidence: GHK-Cu human topical data [1]
The strongest human evidence of any component — controlled dermatological studies showing improved skin firmness, elasticity and wrinkle depth. Topical route, not injection.
Component evidence: BPC-157 rodent tendon and gut healing [2]
Extensive rodent literature on tendon, ligament, gut and vascular healing, predominantly from one research programme.
Component evidence: thymosin β4 anti-fibrotic and repair data [3]
Animal and human topical evidence for the parent protein; the TB-500 fragment is assumed equivalent.
Component evidence: KPV colitis and NF-κB suppression [4]
Rodent colitis models and cell-culture NF-κB work.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Sequential coverage of all four wound-healing phases
The central argument for the blend. Coherent as biology; entirely untested as a combination. Whether four mechanisms delivered simultaneously reproduce a sequence that naturally unfolds over weeks is a real question nobody has asked.
Superior to GLOW because inflammation is addressed
The stated reason KLOW exists. Plausible for chronic inflammatory injury; irrelevant where the problem is purely structural.
Reduced skin laxity during rapid fat loss
The GHK-Cu component supplies the rationale. The most common reason KLOW appears in a metabolic stack.
Symptom relief in fibromyalgia
Anti-inflammatory action from KPV and BPC-157 proposed to modulate systemic pain signalling, with TB-500 and BPC-157 addressing concurrent myofascial pain and poor recovery. The gap in this reasoning is that fibromyalgia is primarily a disorder of central pain processing, and no component of KLOW is proposed to act centrally.
Inflammatory burden in PCOS
Chronic low-grade inflammation is a recognised feature of PCOS, and the KPV/GHK-Cu anti-inflammatory axis is cited as a way to address it. Nothing in the blend acts on insulin resistance or hyperandrogenism — the two mechanisms that define the syndrome.
Mitigation of muscle loss during aggressive caloric deficit
Claimed in circulating protocols. None of the four components has an established anti-catabolic mechanism; resistance training and protein intake — which appear in the same protocols — do.
Reduced post-injection pain versus standalone GHK-Cu
Attributed to BPC-157. Consistently reported, mechanistically uncharacterised.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Broad reduction in joint and tendon pain within 2–4 weeks
The dominant community report. Uncontrolled, unblinded, and confounded by the natural history of soft-tissue complaints.
Visible improvement in skin quality and elasticity
Consistently reported and the component evidence best supports it.
Reduced systemic inflammation and better recovery
Broadly reported and unmeasured.
Injection-site stinging — better than GHK-Cu alone but still present
The most common practical complaint. Mitigations reported: greater dilution volume, slower injection, room-temperature solution, site rotation.
Fatigue on prolonged continuous use
The main practical reason for cycling, generally attributed to copper accumulation.
Reduced deep muscle ache and stiffness in fibromyalgia
Reported decreases in deep muscle ache and joint stiffness, with improved capacity to recover from light exercise. Fibromyalgia symptoms fluctuate substantially on their own, which makes uncontrolled reports in this condition harder to interpret than most.
Skin and fatigue improvements in PCOS
Reported improvements in skin texture and acne, and subjective reductions in fatigue. These are secondary symptoms — no reports describe changes in cycle regularity, androgen markers or insulin resistance, which is what the condition is actually defined by.
Cannot tell which component is doing what
A structural limitation of blends that community reports acknowledge openly. Users who respond well to KLOW frequently cannot say whether GLOW or Wolverine alone would have worked equally.
02 Adverse effects & risks
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No combination safety data exists
No study has assessed the safety of these four peptides administered together, in any species.
Copper toxicity is the characterised risk [5]
Copper excess causes hepatic injury, neurological dysfunction and haemolysis, and antagonises zinc. Injected copper bypasses intestinal absorption control entirely. This is the one component risk with a real human clinical literature behind it.
Angiogenic components in unwanted tissue [3]
Both BPC-157 and TB-500 promote angiogenesis and cell migration. Thymosin β4 expression is associated with tumour progression in oncology literature. Blending them doubles the theoretical exposure to that concern.
No component has long-term human safety data by injection
Not one of the four has a chronic subcutaneous human safety dataset.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Cumulative copper load at unknown ratio
The defining risk of this blend, made worse by the fact that most suppliers do not disclose the split. Daily dosing over months at an undisclosed GHK-Cu fraction means the weekly copper delivery is genuinely unknown.
Zinc depletion and over-correction
Copper loading depresses zinc; correcting with chronic high-dose zinc causes copper deficiency. Both directions cause harm, and neither is guessable without serum copper, ceruloplasmin and zinc.
Stacked pro-proliferative signalling
Angiogenesis (BPC-157), cell migration (TB-500), matrix remodelling (GHK-Cu) and immune suppression (KPV) delivered together is, in theory, a favourable environment for something that should not be growing. Purely theoretical, entirely unstudied, and worth naming.
Chronic NF-κB suppression from KPV
Sustained suppression of the principal inflammatory transcription factor theoretically impairs infection response and immune surveillance.
Unknown endocrine effects — relevant in PCOS
PCOS is an endocrine disorder, and no component of KLOW has been characterised for effects on sex-hormone receptors, the HPG axis or androgen feedback loops. Using an uncharacterised multi-peptide blend in a condition defined by disordered endocrine signalling is a specific unknown, not a general one.
Unpredictable results from artificially altering inflammatory cascades
Both conditions involve immune and inflammatory dysregulation, and KPV suppresses NF-κB while GHK-Cu modulates a broad gene-expression programme. Deliberately shifting those cascades in someone whose inflammatory signalling is already atypical has no characterisation in either direction.
Delaying effective treatment
Both conditions have treatments with randomised evidence behind them. The practical risk of an unproven blend is not only what it does — it is the months spent not doing something that works.
Inability to isolate an adverse effect
If something goes wrong on a blend, four candidate causes must all be stopped together.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Injection-site stinging, redness and nodules
The most reported effect, attributed to the copper component.
Fatigue and malaise on long continuous runs
Copper-consistent; almost never confirmed with a serum measurement.
Metallic taste and headaches
Classic copper excess signals, occasionally reported.
Blend consistency problems between vendors
Reports of markedly different sting, colour and effect between suppliers of nominally the same blend — consistent with unstandardised ratios.
03 Dosing ranges
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No studied dose exists for the blend
Every figure is community-derived. Component study doses are not additive and were established by different routes in different models.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Dose by copper content, not blend mass
The variable that determines cumulative risk is elemental copper delivered per week. Nothing about a "3.25 mg blend" figure conveys that.
Cycle on the copper component, not on the blend
BPC-157 and TB-500 do not have an identified reason to be cycled; GHK-Cu and KPV do. This is precisely the logic behind rotating to the Wolverine stack rather than stopping entirely.
Dilute generously
Larger reconstitution volume reduces the local copper concentration at the injection site and is the most commonly reported mitigation for sting.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
3.25 mg total blend, once daily
The figure specified in the Gold Standard protocol. Run for four vials, then rotate to the Wolverine blend at 1 mg for two vials, then return to KLOW.
1.5–3.5 mg daily depending on blend ratio
The general community range, adjusted by how heavily the vendor weights the GHK-Cu fraction.
Evening administration
Common but arbitrary — none of the components has an established circadian dependency.
Zinc alongside, guided by labs
The circulating protocol notes that zinc may be needed to balance copper but that daily zinc upper limits make bloodwork the sensible prerequisite — the correct instinct.
| Phase | Blend | Daily dose | Duration |
|---|---|---|---|
| Repair phase | KLOW | 3.25 mg | 4 vials |
| Copper break | Wolverine (BPC + TB) | 1 mg | 2 vials |
| Return | KLOW | 3.25 mg | 4 vials |
| General range | KLOW | 1.5 – 3.5 mg | Ratio-dependent |
Work out your own split
If your supplier states the blend ratio, the calculator will break a total blend dose into per-component milligrams and show the syringe units for the whole thing. Open the blend calculator →
04 Synergy & interactions
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No combination studies exist
The blend has never been studied as a blend.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Internal synergy — the four-phase argument
The proposition that each component enables the next. It is the reason the blend exists and it has never been tested against any single component or against the three-component GLOW.
KLOW alongside aggressive fat loss
Skin elasticity and connective tissue support during rapid weight reduction. The most common stack context.
KLOW with GH secretagogues
GH-driven collagen synthesis alongside matrix remodelling. Reasonable on paper; adds another proliferative signal to an already crowded one.
Antagonism to manage: zinc
Zinc is used against the blend rather than with it, to counteract copper loading.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
KLOW ↔ Wolverine rotation
The standard cycling structure, keeping BPC-157 and TB-500 continuous while giving copper and melanocortin exposure a break.
Layered into the Gold Standard protocol as the repair pillar
Position 2 in the circulating protocol, alongside the metabolic and GH pillars.
05 Protocols
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No protocol has ever been studied
There is no trial, animal study or registered protocol for this blend.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
What actually sets the duration — and what does not
Worth separating the two components that drive this decision, because they point opposite ways. The peptide repair components are the argument for running long. BPC-157’s rodent literature is not confined to the injection site — intragastric and intraperitoneal dosing produce distant-organ effects, so it behaves systemically rather than as a local agent. And Tβ4 has the one published head-to-head on schedule: in rat chronic myocardial ischaemia, long-term dosing reduced infarct size and improved function where short-term dosing only trended that way. Human phase 1 work found no accumulation across repeated doses. What limits the course is the copper. GHK-Cu is the component with a cumulative-exposure rationale, and the rotation exists to let copper homeostasis normalise — not because BPC-157 or TB-500 have been shown to lose effect. No tachyphylaxis study exists for either peptide, so “no tolerance” remains an absence of evidence rather than a finding.
Copper-status-guided cycling
Run the blend, measure serum copper, ceruloplasmin and zinc, and let the numbers set the off-period rather than a vial count.
Consider whether the blend is needed at all
If the goal is tendon repair rather than skin quality, Wolverine covers it without any copper. If the goal is skin, topical GHK-Cu has actual human evidence and delivers no systemic copper. The blend is the highest-exposure option of the three.
Mechanical loading alongside
Connective tissue remodels along lines of applied stress. No peptide substitutes for progressive loading in tendon rehabilitation.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Gold Standard Protocol — KLOW 3.25 mg daily, 4 vials then Wolverine
Four vials of KLOW at 3.25 mg daily, then Wolverine blend at 1 mg for two vials, then back to KLOW. BPC-157 and TB-500 are described as never needing cycling, with reported chronic-issue benefit accumulating around the eight-to-nine month mark. Zinc noted for copper balance, with labs recommended first.
15-Compound Matrix — Q2 structural repair
Grouped with the Wolverine stack in the regenerative and tissue repair pillar, introduced in the second quarter after the metabolic and mitochondrial foundations.
6–8 week intensive, then down-titrate
A general community pattern outside the specific protocols above.
05b Condition-specific interest: PCOS & fibromyalgia
KLOW circulates in functional-medicine and wellness spaces for two conditions it has never been tested in. Both are documented here because the interest is real and the reasoning is worth examining — not because either use is supported.
No approval, no trial
Neither the KLOW blend nor any of its four components is approved by the FDA — or any regulator — for the treatment, cure or prevention of polycystic ovary syndrome or fibromyalgia. There are zero human clinical trials evaluating KLOW as a collective entity for any indication, let alone these. Everything below is mechanistic inference and uncontrolled self-report.
Both conditions have established, evidence-based treatments. Choosing an unapproved four-peptide blend over them is a decision to make with a clinician who knows your history, not on the basis of a page like this one.
Theorized + anecdotal only
Fibromyalgia
Pathophysiology
Primarily central nervous system sensitisation — amplified pain processing rather than peripheral tissue damage — with a systemic inflammatory component that remains debated.
Mechanistic rationale
The anti-inflammatory actions of KPV and BPC-157 are proposed to modulate systemic pain signalling, while TB-500 and BPC-157 target musculoskeletal soft tissue, potentially addressing the concurrent myofascial pain and poor recovery many patients report. Note the mismatch: the dominant mechanism in fibromyalgia is central sensitisation, and nothing in KLOW is proposed to act on the CNS. The rationale addresses a secondary feature, not the primary pathology.
Community reports
Users report subjective decreases in deep muscle ache and joint stiffness, and improved capacity to recover from light exercise. Uncontrolled, unblinded, and in a condition characterised by symptom fluctuation — which makes any uncontrolled report especially difficult to interpret.
Components carrying the argument: BPC-157 and TB-500 (musculoskeletal), KPV (inflammatory)
Theorized + anecdotal only
PCOS
Pathophysiology
Insulin resistance and hyperandrogenism are the primary drivers, with chronic low-grade inflammation as a recognised contributing feature.
Mechanistic rationale
The anti-inflammatory axis of KPV and GHK-Cu is cited in functional-medicine spaces as a way to address the systemic inflammatory environment. Note the larger mismatch: nothing in KLOW acts on insulin resistance or androgen production — the two mechanisms that actually define the condition. The argument targets a downstream contributor while leaving the drivers untouched.
Community reports
Users report improvements in skin texture and acne, and subjective reductions in fatigue — secondary symptoms rather than the endocrine or metabolic features of the syndrome.
Components carrying the argument: KPV and GHK-Cu (inflammatory, dermal)
| Attribute | Fibromyalgia | PCOS |
|---|---|---|
| Primary pathophysiology | CNS sensitisation; systemic inflammation | Insulin resistance; hyperandrogenism |
| Components carrying the rationale | BPC-157 & TB-500 | KPV & GHK-Cu |
| Does KLOW address the primary driver? | No — no CNS-acting component | No — no insulin or androgen action |
| Clinical evidence for the blend | None | None |
| Community reports | Less muscle ache, better recovery | Skin quality, less fatigue |
What actually has evidence for these conditions
Fibromyalgia has FDA-approved pharmacotherapy — pregabalin, duloxetine and milnacipran — and the intervention with the strongest evidence base of any kind is graded exercise combined with cognitive behavioural therapy. PCOS has an evidence base spanning metformin for insulin resistance, combined hormonal contraceptives for hyperandrogenism and cycle regulation, letrozole for ovulation induction, inositol, and weight management where relevant — with GLP-1 receptor agonists now studied in the metabolic phenotype.
None of that makes KLOW inert or the interest illegitimate. It does mean the honest comparison is not "peptide versus nothing" but "peptide versus treatments with randomised evidence behind them" — and that comparison rarely gets made in the spaces where this blend is promoted.
06 Handling, reconstitution & storage
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Reconstitution
Supplied as a pre-blended lyophilised vial, most commonly 80 mg total. Reconstituted with bacteriostatic water; larger dilution volumes are widely reported to reduce injection-site sting, and with 50 mg of copper peptide in the vial that matters more here than in any other blend. The solution should carry a strong blue tint.
Storage
Lyophilised: refrigerated or frozen, protected from light. Reconstituted: 2–8 °C. Copper complexes are light-sensitive.
Common vial sizes
Most commonly an 80 mg total vial (50 mg GHK-Cu plus 10 mg each of BPC-157, TB-500 and KPV). At 3.25 mg daily that is about 25 days per vial.
Stability notes
Absence of the characteristic blue tint suggests either no GHK-Cu or a dissociated complex. Cloudiness or particulate indicates degradation or contamination.
07 Legal & regulatory status
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Not approved for human use in any jurisdiction. No component of KLOW is approved, and the blend as a product exists only in the research-chemical market.
The US compounding status of BPC-157, TB-500 and KPV changed materially in 2026 — see their individual monographs — but none of that applies to a multi-component research blend, which has no regulatory standing whatsoever and no manufacturer accountable for its ratio, purity or sterility.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: component status: BPC-157, TB-500 and KPV recommended by PCAC July 2026; GHK-Cu pending Feb 2027. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Anti-doping
BPC-157 and TB-500 are both explicitly prohibited by WADA — BPC-157 under S0, thymosin β4 analogues under S2. Any blend containing them is prohibited at all times for tested athletes.
§ Sources & further reading
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987.Review or meta-analysis
- Sikirić P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011.Review or meta-analysis
- PubMed: thymosin beta 4 — repair, anti-fibrotic activity and tumour-progression association (live query)Database or literature search
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.Pre-clinical / animal study
- NIH Office of Dietary Supplements — Copper: fact sheet for health professionals (upper limits, zinc interaction, toxicity)Regulatory / official document
Reminder
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.